📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Balaji Amines Shuts Plants Due to Ammonia Supply Disruption Amid Middle East Conflict
Balaji Amines has reported a significant disruption in its supply chain due to the ongoing Middle East conflict, which has severely impacted global shipping and logistics. Key suppliers of Ammonia, a critical raw material for the company, have invoked Force Majeure clauses following a shortage of Liquefied Natural Gas (LNG). As a result, several of the company's manufacturing plants are currently non-operational, affecting the production of Methylamines and Ethylamines. While the company is exploring alternative supply sources, the total financial and operational impact remains unquantifiable at this stage.
Key Highlights
Middle East conflict has led to Force Majeure invocations by key Ammonia suppliers.
Shortage of LNG has halted Ammonia production for several Indian manufacturers.
Multiple manufacturing plants of Balaji Amines are currently non-operational due to raw material unavailability.
Production of core products including Methylamines, Ethylamines, and derivatives is significantly affected.
The company is unable to estimate the exact financial impact of the shutdown at this time.
💼 Action for Investors
Investors should prepare for a potential decline in short-term revenue and margins due to plant shutdowns. It is advisable to monitor the duration of the Force Majeure and the company's progress in securing alternative Ammonia supplies.
Balaji Amines Q3FY26: Revenue Up 4.9% YoY to ₹336 Cr; EBITDA Margins Improve to 18.3%
Balaji Amines reported a mixed Q3FY26 with consolidated revenue growing 4.9% YoY to ₹336.29 crore, though it declined 3.26% sequentially. While EBITDA grew 15.12% YoY to ₹61.67 crore with margins expanding to 18.34%, PAT saw a slight YoY dip of 1.22% to ₹30.76 crore. Total sales volumes increased to 25,894 MT from 24,097 MT YoY, driven by steady demand in specialty chemicals and amines. The company is aggressively pursuing a ₹750 crore expansion in its subsidiary and expects several new plants to commission in FY27.
Key Highlights
Consolidated Revenue grew 4.9% YoY to ₹336.29 Cr, supported by a volume increase to 25,894 MT.
EBITDA margins improved to 18.34% from 16.71% YoY, despite a 7.78% QoQ drop in EBITDA.
PAT for Q3FY26 stood at ₹30.76 Cr, reflecting a 17.09% sequential decline due to higher tax and depreciation.
Methylamines capacity successfully expanded to 88,000 TPA; ₹750 Cr expansion underway in subsidiary for HCN and EDTA products.
Standalone entity remains zero-debt, with all new projects funded through internal accruals.
💼 Action for Investors
Investors should monitor the progress of the ₹750 crore expansion and the commissioning of the DME plant in FY27, which are key growth catalysts. The current margin recovery is encouraging, but sequential PAT pressure warrants a cautious hold until volume growth translates to bottom-line stability.
Balaji Amines Q3FY26 Consolidated PAT at ₹31 Cr; ₹750 Cr Expansion Underway
Balaji Amines reported a consolidated revenue of ₹336.29 crore for Q3FY26, a slight decline from ₹347.61 crore in the previous quarter. Net profit for the quarter stood at ₹30.76 crore, down from ₹37.10 crore in Q2FY26, with EBITDA margins contracting to 18.34%. Despite near-term pressure from the pharma and agrochemical segments, the company is moving ahead with a ₹750 crore expansion plan in its subsidiary, which has received 'Mega Project' status. Several new plants, including DME and Acetonitrile, are expected to be commissioned in FY 2026-27.
Key Highlights
Consolidated PAT for Q3FY26 decreased to ₹30.76 crore from ₹37.10 crore in Q2FY26.
EBITDA margin stood at 18.34% for the quarter, compared to 19.24% in the previous quarter.
Total sales volume for Q3FY26 was 25,894.09 MT, with Specialty Chemicals accounting for 9,678.27 MT.
Announced a ₹750 crore phased expansion in subsidiary Balaji Speciality Chemicals for products like Sodium Cyanide and EDTA.
The company maintains a zero-debt status on a standalone basis, funding projects through internal accruals.
💼 Action for Investors
Investors should monitor the margin recovery and the progress of the ₹750 crore capex, as significant growth is tied to the FY27 commissioning of new plants. The current slowdown in the pharmaceutical and agrochemical sectors remains a key headwind to watch.
Balaji Amines Q3 Consolidated PAT Declines 17% QoQ to ₹30.76 Crore
Balaji Amines reported a mixed performance for Q3 FY26, with consolidated revenue growing 5.9% YoY to ₹331.30 crore but declining 2.7% sequentially. Profitability faced significant pressure as consolidated PAT fell 17% QoQ to ₹30.76 crore, impacted by higher raw material costs and increased finance charges. The core Amines & Speciality Chemicals segment remains the primary driver, contributing over 97% of total revenue. On a nine-month basis, PAT stands at ₹104.39 crore, down from ₹118.15 crore in the previous year, indicating a challenging margin environment.
Key Highlights
Consolidated Revenue from operations stood at ₹331.30 crore, a 5.9% increase compared to ₹312.73 crore in Q3 FY25.
Consolidated Net Profit (PAT) dropped to ₹30.76 crore, down 17% from ₹37.10 crore in the preceding quarter.
Earnings Per Share (EPS) for the quarter decreased to ₹9.49 from ₹10.24 in the same period last year.
The Amines & Speciality Chemicals segment reported a profit before tax of ₹41.99 crore, down from ₹49.38 crore in Q2 FY26.
Total consolidated expenses for the quarter rose to ₹290.31 crore, reflecting margin compression compared to the previous quarter.
💼 Action for Investors
Investors should exercise caution due to the significant sequential decline in profitability and margin pressure. Monitor raw material price trends and volume growth in the speciality chemicals segment before making new entries.
Balaji Amines Receives ₹258 Crore Incentive Certificate for Unit-4 Expansion
Balaji Amines has received an Eligibility Certificate from the Government of Maharashtra for its Unit-4 expansion under the Mega Projects scheme. The company is entitled to incentives totaling ₹258.01 crore over a seven-year period ending December 2030. These incentives include a 50% SGST subsidy on sales within Maharashtra, along with exemptions from electricity and stamp duties. This development is expected to significantly lower operational costs and improve the net profitability of the Unit-4 facility.
Key Highlights
Total incentive entitlement of ₹258.01 crore under the Package Scheme of Incentives-2013
Incentives are valid for a 7-year period from January 1, 2024, to December 31, 2030
Entitlement includes 50% Industrial Promotion Subsidy (IPS) on SGST payable for sales in Maharashtra
Provides 100% exemption from Stamp Duty and full Electricity Duty exemption for the unit
💼 Action for Investors
This is a positive development that will boost cash flows and margins for the next seven years. Investors should monitor the ramp-up of Unit-4 to see how effectively these tax benefits translate into bottom-line growth.